Guideline Recommendations for Pediatric Nephrotic Syndrome Based on Steroid Response

Classification‑Based Management

Frequently relapsing nephrotic syndrome (FRNS) in children warrants early introduction of steroid‑sparing agents to limit cumulative corticosteroid toxicity. (Kidney International, 2025) 1
All children with steroid‑dependent nephrotic syndrome (SDNS) should receive glucocorticoid‑sparing therapy rather than continued corticosteroids alone. (Kidney International, 2025) 1

Low‑dose, alternate‑day oral prednisone/prednisolone can be employed for relapse prevention when glucocorticoid toxicity is absent. (Kidney International, 2025) 1
Routine daily glucocorticoids during upper‑respiratory‑tract infections should be avoided, as this practice does not reduce relapse risk in FRNS or SDNS patients. (Kidney International, 2025) 1

Oral cyclophosphamide (≈2 mg/kg/day for 8–12 weeks) or levamisole (≈2.5 mg/kg on alternate days) are preferred first‑line steroid‑sparing agents. (Kidney International, 2025) 1

Mycophenolate mofetil, rituximab, calcineurin inhibitors (cyclosporin or tacrolimus), or cyclophosphamide are recommended options for SDNS. (Kidney International, 2025) 1

Cyclosporin or tacrolimus should be initiated as the first second‑line therapy in children with SRNS. (Kidney International, 2025) 1
Rituximab can induce remission in roughly 30 % of children whose SRNS is resistant to calcineurin inhibitors. (Kidney International, 2025) 1
In complex FRNS or SDNS cases, sequential use of rituximab followed by mycophenolate mofetil reduces the risk of treatment failure. (Kidney International, 2025) 1

Patients should achieve remission on glucocorticoids before starting a glucocorticoid‑sparing agent. (Kidney International, 2025) 1
Glucocorticoids are continued for approximately 2 weeks after the initiation of a steroid‑sparing agent. (Kidney International, 2025) 1
If signs of glucocorticoid toxicity emerge, clinicians should adopt a shorter steroid taper and employ more aggressive steroid‑sparing strategies in subsequent relapses. (Kidney International, 2025) 1

The KDIGO Work Group no longer categorizes agents as strictly “first‑line” or “alternative,” allowing individualized selection of steroid‑sparing therapies based on patient‑specific factors. (Kidney International, 2025) 1

All statements are derived from the cited Kidney International 2025 guideline (citation 1).

The American Academy of Pediatrics recommends starting oral prednisone 60 mg/m²/day or 2 mg/kg/day (maximum 60 mg/day) as a single morning dose for 4-6 weeks, followed by alternate-day prednisone 40 mg/m² for 2-5 months in pediatric patients with nephrotic syndrome 2, 3, 4
Total treatment duration should be 8-12 weeks minimum, with longer initial courses up to 6 months reducing relapse risk 2, 3, 4, 5
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest that children with frequent relapses or steroid-dependent disease should be prescribed glucocorticoid-sparing agents rather than continuing corticosteroids alone 2, 3

For infrequent relapses, the KDIGO guidelines recommend treating with prednisone 60 mg/m²/day until 3 consecutive days of remission, then switching to alternate-day prednisone 40 mg/m² for 4 weeks 4, 6
For frequently relapsing disease, cyclophosphamide (2 mg/kg/day for 8-12 weeks) or levamisole (2.5 mg/kg alternate days) are preferable 2, 3, 5
For steroid-dependent disease, mycophenolate mofetil, rituximab, calcineurin inhibitors (cyclosporine/tacrolimus), or cyclophosphamide are preferable 2, 3
The KDIGO guidelines recommend using cyclosporine or tacrolimus as initial second-line therapy for steroid-resistant disease 3

The American Academy of Pediatrics recommends supportive care only for nephritic syndrome, including fluid and sodium restriction, antihypertensive therapy, and monitoring for complications 2, 4, 5
Antibiotics should only be used if active streptococcal infection is documented (penicillin for 10 days) 2
The disease is typically self-limited, with most children recovering completely within 2-4 weeks without immunosuppression 5